RBC Capital analyst Gregory Renza maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $13.00.

RBC Capital analyst Gregory Renza maintained a Buy rating on Nuvation Bio (NUVB – Research Report) today and set a price target of $6.00.

Fintel reports that on November 5, 2024, RBC Capital downgraded their outlook for Verrica Pharmaceuticals (NasdaqGM:VRCA) ...

Helima Croft, RBC Capital Market's head of global commodity strategy weighs in on how the energy sector would be impacted by ...

Investing.com -- Shares of Burberry (LON: BRBY) saw a rise on Wednesday following an upgrade by RBC Capital Markets to an "outperform" rating from a "sector perform” rating, accompanied by a price ...

Chief Financial Officer Mark McCaffrey will present at the 2024 RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference in New York City on Tuesday, November 19, 2024, ...

Gold and silver futures fell Wednesday as traders anxious about the election pulled out of the safe-haven assets. Prices for ...

RBC Capital Markets believes the U.S. election could serve as a key clearing moment for stocks, with positive effects on the ...

Fidelity National Information Services beats Q3 estimates, and raises full-year outlook Analysts maintain rating.

Duke Energy ( NYSE: DUK) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market opens. The ...

Interest rate-sensitive areas of the market and cryptocurrencies are among some of the areas expected to see big moves based ...

Lineage Inc.’s first quarterly report after raising $5.1 billion in the year’s biggest US initial public offering will be a ...